MX2021015034A - Composiciones de lactobacillus y usos de las mismas. - Google Patents

Composiciones de lactobacillus y usos de las mismas.

Info

Publication number
MX2021015034A
MX2021015034A MX2021015034A MX2021015034A MX2021015034A MX 2021015034 A MX2021015034 A MX 2021015034A MX 2021015034 A MX2021015034 A MX 2021015034A MX 2021015034 A MX2021015034 A MX 2021015034A MX 2021015034 A MX2021015034 A MX 2021015034A
Authority
MX
Mexico
Prior art keywords
deleterious effect
lactobacillus
strain
psychosocial stress
lactobacillus compositions
Prior art date
Application number
MX2021015034A
Other languages
English (en)
Inventor
Magnus Hillman
Siv Ahrné
Önning Gunilla
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Publication of MX2021015034A publication Critical patent/MX2021015034A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere al menos a una cepa de Lactobacillus para su uso en un método para reducir y/o prevenir al menos un efecto deletéreo de estrés psicosocial agudo en un ser humano, en donde el método comprende el tratamiento mediante la administración de una dosis eficaz de la al menos una cepa de. El al menos un efecto deletéreo puede ser un nivel elevado de fractalquina soluble y puede estar en combinación con al menos un efecto deletéreo adicional de estrés psicosocial agudo.
MX2021015034A 2019-06-07 2020-06-05 Composiciones de lactobacillus y usos de las mismas. MX2021015034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1908154.6A GB201908154D0 (en) 2019-06-07 2019-06-07 Lactobacillus compositions and uses thereof
PCT/EP2020/065620 WO2020245350A1 (en) 2019-06-07 2020-06-05 Lactobacillus compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2021015034A true MX2021015034A (es) 2022-01-18

Family

ID=67386355

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015034A MX2021015034A (es) 2019-06-07 2020-06-05 Composiciones de lactobacillus y usos de las mismas.

Country Status (10)

Country Link
US (1) US20220305064A1 (es)
EP (1) EP3980040A1 (es)
KR (1) KR20220019758A (es)
CN (1) CN113939303A (es)
AU (1) AU2020289216A1 (es)
BR (1) BR112021024644A2 (es)
CA (1) CA3139770A1 (es)
GB (1) GB201908154D0 (es)
MX (1) MX2021015034A (es)
WO (1) WO2020245350A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102501958B1 (ko) * 2022-05-24 2023-02-21 주식회사 한국인삼공사 인삼으로부터 유래한 신규 락토바실러스 퍼멘텀 균주 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE523771C2 (sv) 1999-05-21 2004-05-18 Probi Ab Sportdryck innehållande mikronäringsämnen i kombination med levande laktobaciller
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
ES2398910T3 (es) 2001-09-28 2013-03-22 Tntgamble, Inc. Sistema de aporte para componentes biológicos
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
JP5932662B2 (ja) * 2009-12-22 2016-06-08 プロビ アクティエボラーグ 穀物ベースフラクション及びプロバイオティックを含む非発酵組成物、並びにそれらの使用
EP2658560A1 (en) * 2010-12-29 2013-11-06 Nestec S.A. A nutritional composition comprising fiber and probiotics for reducing stress-related intestinal symptoms
CN106535909A (zh) 2014-07-01 2017-03-22 普罗比美国公司 双层双重释放益生菌片剂
EP3359173A1 (en) 2015-10-07 2018-08-15 Bifodan A/S Probiotic formulation
GB201708932D0 (en) 2017-06-05 2017-07-19 Probi Ab Microbial compositions
CA3137378A1 (en) * 2019-05-06 2020-11-12 Dupont Nutrition Biosciences Aps Probiotics for mental health

Also Published As

Publication number Publication date
EP3980040A1 (en) 2022-04-13
KR20220019758A (ko) 2022-02-17
CA3139770A1 (en) 2020-12-10
GB201908154D0 (en) 2019-07-24
BR112021024644A2 (pt) 2022-01-18
CN113939303A (zh) 2022-01-14
WO2020245350A1 (en) 2020-12-10
AU2020289216A1 (en) 2022-01-27
US20220305064A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
PH12020500352A1 (en) Therapeutic uses of empagliflozin
MD3313422T2 (ro) Compoziții cuprinzând o tulpină bacteriană de Blautia hydrogenotrophica pentru utilizare în tratamentul sau prevenirea diareei sau constipației
PH12020550936A1 (en) Combination drug including tlr7 agonist
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
SG10201908380TA (en) Treatment of fibrosis
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MX2020013740A (es) Uso de empagliflozina para el tratamiento de trastornos metabolicos, la prevencion, y para la reduccion del riesgo de sufrir o para retrasar la ocurrencia de un episodio cardiovascular.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
MX2018006905A (es) Bifidobacterium longum para el tratamiento de la obesidad y trastornos metabolcos asociados.
WO2019067405A3 (en) FORMULATION OF FENFLURAMINE COMPATIBLE WITH A CÉTOGENEOUS REGIMEN
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
NZ756936A (en) Composition and method for preventing or delaying onset of myopia comprising atropine
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2022016243A (es) Antagonistas de actrii-alk4 y métodos para el tratamiento contra insuficiencia cardíaca.
MX2021015034A (es) Composiciones de lactobacillus y usos de las mismas.
WO2019204332A3 (en) Pak4 inhibitors and methods of use
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination